

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Risankizumab for treating active psoriatic arthritis
after inadequate response to DMARDs**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No equality issues were identified during scoping.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No

- | |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? |
|--|

If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

There is the potential that physical, sensory or learning disabilities or communication difficulties could affect a person's responses to components of the PsARC. Additionally, the PASI might underestimate disease severity in people with darker skin.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

The committee noted that other appraisals in the same disease area had included recommendations that healthcare professionals should take into account skin colour/physical, sensory or learning disabilities or communication difficulties when using the PASI/PsARC.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

These issues are reflected in recommendations 1.4 and 1.5, and detailed in section 3.9.

Approved by Associate Director (name): Ross Dent

Date: 26/05/2022